Schizophrenia has a profound influence on the real-life functioning of patients. There are several factors inherent to the disease course affecting the level of psychosocial functioning. Our study focused on the impact of cognitive deficit and severity of negative symptoms (i.e., the experiential domain (avolition, asociality, and anhedonia) and the expressive domain (blunted affect and alogia)) to explore psychosocial functioning in schizophrenia. Schizophrenia patients (n = 211) were tested for the presence of cognitive impairment using the NIMH-MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Cattery (MCCB; MATRICS Consensus Cognitive Battery) and the extent of negative symptoms using the PANSS (PANSS; Positive and Negative Syndrome Scale-selected items). The level of psychosocial functioning was measured with the Personal and Social Performance Scale (PSP). The path analysis using three regression models was used to analyse variables influencing psychosocial functioning (PSP). One of these models analyzed influence of cognitive functioning (MCCB) and negative schizophrenia symptoms (PANSS selected items reflecting expressive and experiential deficits) as predictors and NART/CRT and disease length as confounders. R2 was 0.54. The direct effect of the MCCB (β = 0.09) on the PSP was suppressed by the strong effect of the negative symptoms (β = -0.64). The presence of cognitive deficits and negative symptoms in our sample of schizophrenia patients significantly influences the level of their psychosocial functioning, a key factor in remission and recovery.

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Prague Charles University Prague Czech Republic

Department of Psychiatry 1st Faculty of Medicine and General University Hospital Prague Charles University Prague Czech Republic

Department of Psychiatry Faculty Hospital Ostrava Czech Republic

Department of Psychology Faculty of Arts Charles University Prague Czech Republic

Zobrazit více v PubMed

Charlson FJ, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr. Bull. 2018;44:1195–1203. doi: 10.1093/schbul/sby058. PubMed DOI PMC

Owen MJ, Sawa A, Mortensen PB. Schizophrenia. The Lancet. 2016;388:86–97. doi: 10.1016/S0140-6736(15)01121-6. PubMed DOI PMC

Marwaha S, et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br. J. Psych. 2007;191:30–37. doi: 10.1192/bjp.bp.105.020982. PubMed DOI

Vita A, Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psych. 2018;31:246–255. doi: 10.1097/YCO.0000000000000407. PubMed DOI

Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr. Bull. 2009;35:300–306. doi: 10.1093/schbul/sbn171. PubMed DOI PMC

Huxley P, et al. Schizophrenia outcomes in the 21st century: A systematic review. Brain Behav. 2021;11:e02172. doi: 10.1002/brb3.2172. PubMed DOI PMC

Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psych. 2014;75:8–14. doi: 10.4088/JCP.13049su1c.02. PubMed DOI

Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psych. Services (Washington, D.C.) 2005;56:735–742. doi: 10.1176/appi.ps.56.6.735. PubMed DOI

Jääskeläinen E, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 2013;39:1296–1306. doi: 10.1093/schbul/sbs130. PubMed DOI PMC

Andreasen NC, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psych. 2005;162:441–449. doi: 10.1176/appi.ajp.162.3.441. PubMed DOI

Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy. Front. Psych. 2021;12:781946. doi: 10.3389/fpsyt.2021.781946. PubMed DOI PMC

Krause M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psych. Clin. Neurosci. 2018;268:625–639. doi: 10.1007/s00406-018-0869-3. PubMed DOI

Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399:473–486. doi: 10.1016/S0140-6736(21)01730-X. PubMed DOI

Vita A, et al. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur. Psych. 2022;65:e57. doi: 10.1192/j.eurpsy.2022.2315. PubMed DOI PMC

Galderisi S, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur. Psych. 2021;64:e21. doi: 10.1192/j.eurpsy.2021.13. PubMed DOI PMC

Best MW, Gupta M, Bowie CR, Harvey PD. A Longitudinal Examination of the Moderating Effects of Symptoms on the Relationship between Functional Competence and Real World Functional Performance in Schizophrenia. Schizophr. Res. Cognition. 2014;1:90–95. doi: 10.1016/j.scog.2014.03.002. PubMed DOI PMC

Harvey PD, Loewenstein DA, Czaja SJ. Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiol. Dis. 2013;53:18–25. doi: 10.1016/j.nbd.2012.10.022. PubMed DOI PMC

Reichenberg A, et al. The Course and Correlates of Everyday Functioning in Schizophrenia. Schizophr. Res. Cognition. 2014;1:e47–e52. doi: 10.1016/j.scog.2014.03.001. PubMed DOI PMC

Chang WC, Hui CLM, Chan SKW, Lee EHM, Chen EYH. Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study. Schizophr. Res. 2016;170:318–321. doi: 10.1016/j.schres.2016.01.004. PubMed DOI

Christensen TØ. The influence of neurocognitive dysfunctions on work capacity in schizophrenia patients: a systematic review of the literature. Int. J. Psych. Clin. Practice. 2007;11:89–101. doi: 10.1080/13651500600969061. PubMed DOI

Galderisi S, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psych. Official J. World Psych. Ass. (WPA) 2014;13:275–287. PubMed PMC

Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J. Clin. Psych. 2016;77:8–11. doi: 10.4088/JCP.14074su1c.02. PubMed DOI

Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004;72:41–51. doi: 10.1016/j.schres.2004.09.009. PubMed DOI

Kharawala S, et al. The relationship between cognition and functioning in schizophrenia: A semi-systematic review. Schizophr. Res. Cognition. 2022;27:100217. doi: 10.1016/j.scog.2021.100217. PubMed DOI PMC

Silberstein J, Harvey PD. Cognition, social cognition, and Self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes. CNS Spectrums. 2019;24:88–93. doi: 10.1017/S1092852918001414. PubMed DOI PMC

Fett A-KJ, et al. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis. Neurosci. Biobehav. Rev. 2011;35:573–588. doi: 10.1016/j.neubiorev.2010.07.001. PubMed DOI

Voráčková V, et al. Cognitive profiles of healthy siblings of first-episode schizophrenia patients. Early Interv. Psych. 2021;15:554–562. doi: 10.1111/eip.12982. PubMed DOI

McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin. Neurosci. 2019;21:239–248. doi: 10.31887/DCNS.2019.21.3/amccleery. PubMed DOI PMC

Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psych. 2008;165:214–220. doi: 10.1176/appi.ajp.2007.07010043. PubMed DOI

Nuechterlein KH, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psych. 2008;165:203–213. doi: 10.1176/appi.ajp.2007.07010042. PubMed DOI

Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psych. Official J. World Psych. Ass. (WPA) 2019;18:146–161. PubMed PMC

Pinkham AE, Penn DL, Green MF, Harvey PD. Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study. Schizophr. Bull. 2016;42:494–504. doi: 10.1093/schbul/sbv056. PubMed DOI PMC

Halverson TF, et al. Pathways to functional outcomes in schizophrenia spectrum disorders: Meta-analysis of social cognitive and neurocognitive predictors. Neurosci. Biobehav. Rev. 2019;105:212–219. doi: 10.1016/j.neubiorev.2019.07.020. PubMed DOI

Addington J, Girard TA, Christensen BK, Addington D. Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders. J. Psych. Neurosci. JPN. 2010;35:49–54. PubMed PMC

Cowman M, et al. Cognitive Predictors of Social and Occupational Functioning in Early Psychosis: A Systematic Review and Meta-analysis of Cross-Sectional and Longitudinal Data. Schizophr. Bull. 2021;47:1243–1253. doi: 10.1093/schbul/sbab033. PubMed DOI PMC

Schmidt SJ, Mueller DR, Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr. Bull. 2011;37:S41–S54. doi: 10.1093/schbul/sbr079. PubMed DOI PMC

Sarkar S, Hillner K, Velligan DI. Conceptualization and treatment of negative symptoms in schizophrenia. World J. Psych. 2015;5:352–361. doi: 10.5498/wjp.v5.i4.352. PubMed DOI PMC

Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet. Psych. 2018;5:664–677. doi: 10.1016/S2215-0366(18)30050-6. PubMed DOI

Galderisi S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur. Psych. 2021;64:e23. doi: 10.1192/j.eurpsy.2021.11. PubMed DOI PMC

Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizoph. Bull. 2006;32:214–219. doi: 10.1093/schbul/sbj053. PubMed DOI PMC

Giordano GM, Caporusso E, Pezzella P, Galderisi S. Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert. Rev. Neurother. 2022;22:541–555. doi: 10.1080/14737175.2022.2092402. PubMed DOI

Strauss GP, Ahmed AO, Young JW, Kirkpatrick B. Reconsidering the Latent Structure of Negative Symptoms in Schizophrenia: A Review of Evidence Supporting the 5 Consensus Domains. Schizoph. Bull. 2019;45:725–729. doi: 10.1093/schbul/sby169. PubMed DOI PMC

Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Dis. Treat. 2020;16:519–534. doi: 10.2147/NDT.S225643. PubMed DOI PMC

Levine SZ, Leucht S. Attaining and sustaining remission of predominant negative symptoms. Schizoph. Res. 2013;143:60–64. doi: 10.1016/j.schres.2012.11.010. PubMed DOI

Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am. J. Psych. 2010;167:686–693. doi: 10.1176/appi.ajp.2009.09060802. PubMed DOI

Harvey PD, Khan A, Keefe RSE. Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Innov. Clin. Neurosci. 2017;14:18–22. PubMed PMC

Khan A, et al. Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. Innov. Clin. Neurosci. 2017;14:30–40. PubMed PMC

El Yazaji M, et al. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophr. Res. 2002;56:121–127. doi: 10.1016/S0920-9964(01)00247-X. PubMed DOI

Leucht S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr. Bull. 2014;40:314–326. doi: 10.1093/schbul/sbu001. PubMed DOI PMC

Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta. Psych. Scandinavica. 2000;101:323–329. doi: 10.1111/j.1600-0447.2000.tb10933.x. PubMed DOI

Bezdicek O, Nikolai T, J M, Harsa P, Kališová L. A comprehensive assessment of neurocognitive function in schizophrenia - MATRICS consensus cognitive battery Czech version. Ceska a slovenska Psychiatrie. 2015;111:79–86.

Green MF, Nuechterlein KH. The MATRICS initiative: Developing a consensus cognitive battery for clinical trials. Schizoph. Res. 2004;72:1–3. doi: 10.1016/j.schres.2004.09.006. PubMed DOI

Bezdicek O, et al. Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery. Schizoph. Res. 2020;218:85–92. doi: 10.1016/j.schres.2020.02.004. PubMed DOI

Green MF, et al. Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study. Am. J. Psych. 2008;165:221–228. doi: 10.1176/appi.ajp.2007.07010089. PubMed DOI

Havlik F, et al. The normative data study of the Czech MATRICS consensus cognitive battery. Clin. Neuropsychologist. 2021;35:S50–S64. doi: 10.1080/13854046.2021.1962410. PubMed DOI

Kalisova L, et al. Cognitive functioning in patients treated with electroconvulsive therapy. Neuropsych. Dis. Treat. 2018;14:3025–3031. doi: 10.2147/NDT.S182423. PubMed DOI PMC

Nelson, H. The national adult reading test (NART): Test Manual. (Windsor: NFER-NELSON, 1982).

Kramska, L. Assessment of premorbid intellect in neuropsychology. Czech reading test. (Propsyco, 2014).

Rodriguez M, et al. The relationships between cognitive reserve, cognitive functioning and quality of life in first-episode schizophrenia spectrum disorders. Psych. Res. 2022;310:114479. doi: 10.1016/j.psychres.2022.114479. PubMed DOI

Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psych. 2012;11:73–79. doi: 10.1016/j.wpsyc.2012.05.004. PubMed DOI PMC

Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. European Psych. J. Ass. European Psych. 2012;27:432–436. PubMed

Strassnig M, et al. Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? J. Psych. Res. 2018;104:124–129. doi: 10.1016/j.jpsychires.2018.06.018. PubMed DOI

Quinlan T, Roesch S, Granholm E. The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia. Schizophr. Rese. 2014;157:182–189. doi: 10.1016/j.schres.2014.05.025. PubMed DOI PMC

Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Archives General Psych. 2012;69:1216–1224. doi: 10.1001/archgenpsychiatry.2012.652. PubMed DOI PMC

Okada H, Hirano D, Taniguchi T. Single versus dual pathways to functional outcomes in schizophrenia: Role of negative symptoms and cognitive function. Schizophr. Res. Cognition. 2021;23:100191. doi: 10.1016/j.scog.2020.100191. PubMed DOI PMC

Jauhar S, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British J. Psych. J. Mental Sci. 2014;204:20–29. doi: 10.1192/bjp.bp.112.116285. PubMed DOI

Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008;34:523–537. doi: 10.1093/schbul/sbm114. PubMed DOI PMC

Cella M, Preti A, Edwards C, Dow T, Wykes T. Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis. Clin. Psychol. Rev. 2017;52:43–51. doi: 10.1016/j.cpr.2016.11.009. PubMed DOI

Fusar-Poli P, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2015;41:892–899. doi: 10.1093/schbul/sbu170. PubMed DOI PMC

Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psych. 2011;168:472–485. doi: 10.1176/appi.ajp.2010.10060855. PubMed DOI

Allott K, et al. Compensatory interventions for cognitive impairments in psychosis: A systematic review and meta-analysis. Schizophr. Bull. 2020;46:869–883. doi: 10.1093/schbul/sbz134. PubMed DOI PMC

Longitudinal course of core cognitive domains in first-episode acute and transient psychotic disorders compared with schizophrenia